最新医学別冊　新しい診断と治療のABC50/消化器7　肝癌

出版社： 最新医学社
発行日： 2007-10-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 肝癌
電子書籍版： 2007-10-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC50/消化器7　肝癌

    ―目次―

    特集　肝癌

    第１章　概念・病因と疫学
    　概念・病因 　
    　疫学 　

    第２章　病理・病態生理
    　病理 　
    　発がん機序 　
    　病態生理

    第３章　診断
    　血液検査 　
    　腫瘍マーカー 　
    　画像診断
    　　(1) 超音波検査 　
    　　(2) CT・MRI 　
    　病期分類 　
    　肝腫瘤性病変の鑑別診断 　

    第４章　管理・治療
    　肝発がんの予防　
    　早期発見　
    　内科的治療
    　　(1)　PEIT・RFA・MCT 　
    　　(2)　TAE 　
    　　(3)　リザバー動注化学療法 　
    　　(4)　全身化学療法 済生会新潟第二病院 石川　達
    　外科療法
    　　(1) 肝切除 　
    　　(2)　肝移植 　
    　特殊な治療 　
    　進行肝癌の治療 　
    　経過・予後 　
    　再発予防 　
    　肝癌治療の医療経済 　

    第５章　ガイドライン
    　ガイドラインに基づいた治療戦略

    座談会
    　肝癌治療の現況と展望 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第2章 病理・病態生理

P.15 掲載の参考文献
1) 日本肝癌研究会 編:臨床・病理 原発性肝癌取扱い規約[第4版], p 1-2. 金原出版株式会社, 東京, 2001.
 
2) 日本肝癌研究会追跡調査委員会:第17回全国原発性肝癌追跡調査報告 (2002-2003). 肝臓 48 (3):117-140, 2007.
 
3) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 (9):1065-1067, 1998.
PubMed
4) Matsubara K, et al:Integration of hepatitis B virus and its implication for hepatocarcinogenesis. Mol Biol Med 7:243-260, 1990.
 
5) Wang Y, et al:Characterization of HBV integrants in 14 hepatocellular carcinomas:association of truncated X gene and hepatocellular carcinogenesis. Oncogene 23 (1):142-148, 2004.
PubMed
6) Tang H, et al:Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 97 (10):977-983, 2006.
PubMed
7) Shiota G, et al:Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population:Involvment of HBx and p 53. J Medical Virol 62:151-158, 2000.
 
8) Donato F, et al:Alcohol and hepatocellular carcinoma the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (4):323-331, 2002.
PubMed
9) Seitz H K, et al:Alcohol and cancer. Recent Dev Alcohol 14:67-95, 1998.
PubMed
10) 日本肝臓学会編:NASH・NAFLDの診療ガイド. 文光堂, 東京, 2006.
 
11) Shimada M, et al:Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37 (1):154-160, 2002.
PubMed
12) Sumida Y, et al:Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 38 (1):32-38, 2003.
PubMed
13) Davila J A, et al:Diabetes increases the risk of hepatocellular carcinoma in the United States:a population based case control study. Gut 54 (4):533-539, 2005.
PubMed
14) Shibuya A, et al:Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35 (5):1172-1178, 2002.
PubMed
15) Park S Z, et al:Hepatocelular carcinoma in autoimmune hepatitis. Dig Dis Sci 45 (10):1944-1948, 2000.
 
16) Fevery J, et al:Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007. (Epub ahead of print)
 
17) Boberg K M, et al:Cholangiocarcinoma in primary sclerosing cholangitis:risk factors and clinical presentation. Scand J Gastroenterol 37 (10):1205-1211, 2002.
PubMed
18) Denise M, et al:Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 27:512-516, 1997.
 
19) Izumi Y, et al:Juvenile hepatocellular carcinoma with congestive liver cirrhosis. J Gastroenterol 40:204-208, 2005.
PubMed
20) Fargion S, et al:Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 20 (6):1426-1431, 1994.
PubMed
21) Zhou H, et al:Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 88 (12):2668-2676, 2000.
PubMed
22) Foster PL, et al:Base substitution mutations induced by metabolically activated afiatoxin B1. Proc Natl Acad Sci USA 80 (9):2695-2698, 1983.
 
23) 水本龍二, 他:経口避妊薬と肝癌. 肝胆膵 5:1007-1012, 1982.
 
P.24 掲載の参考文献
1) 厚生労働省:平成18年人口動態統計月報年計 (概数) の概況, 2007.
 
2) 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告 (2002-2003), 2006.
 
3) Taura N, et al:Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging:Long term trends in Japan. Hepatol Res 34 (2):130-134, 2006.
PubMed
4) Yoshizawa H, et al:Hepatocellular carcinoma associated with hepatitis C virus infection in Japan:Projection to other countries in the foreseeable. Oncology 62 (Suppl 1):8-17, 2002.
PubMed
5) Yatsuhashi H, et al:Towards Control of Hepatitis C in the Asia-Pacific Region. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 15 (Suppl):E 111-E 116, 2000.
 
6) Hamada H, et al:Impact of Aging on the Development of Hepatocellular Carcinoma in Patients with Posttransfusion Chronic Hepatitis C. Cancer 95 (2):331-339, 2002.
PubMed
7) Hamada H, et al:Interleukin-10 promoter polymorphisms and liver fibrosis progression in patients with chronic hepatitis C in Japan. J Hepatol 39 (3):457-458, 2003.
PubMed
8) 八橋 弘:わが国のC型肝炎の現状日本の肝癌は, なぜ多いのか. 日消会誌101 (6):578-584, 2004.
 
P.32 掲載の参考文献
1) Kojiro M:pathological evolution of early hepatocellular carcinoma. Oncology 62 (suppl 1):43-47, 2002.
 
2) 中島 収:肝細胞癌の多中心性発生の病理形態的判定基準. 肝胆膵 36 (2):173-176, 1998.
 
3) 中島 収他:再発のメカニズム;病理形態学的観点から. 肝胆膵39 (6):757-760, 1999.
 
4) Sakamoto M, et al:Early stage of multistep hepatocarcinogenesis:Adenomatous hyperplasia and early hepatocellular carcinoma Hum Pathol 22:172-178, 1991.
 
5) Nakashima O, et al:Pathomorphologic characteristics of small hepatocellular carcinoma:A special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 22:101-105, 1995.
PubMed
6) Sakamoto M, et al:Natural history and prognosis of adellomatous hyperplasia and early hepatocellular carcinoma; Multi-institusional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or Percutaneous ethanol injection. Jpn J Clin Oncol 28:604-608, 1998.
PubMed
7) 中島 収:肝癌の形態発生と進展:消化器病 UP TO DATE-Consensus & Controversies (小林絢三偏), p 22-26. 永井書店, 大阪,1996.
 
8) 枝光 理:肝細胞癌腫瘍血管に関する病理学的研究-主に血管数について-. 肝臓 33:15-20, 1992.
 
9) Kutami R, et al:Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282-289, 2000.
 
10) Suzuki T, et al:β-Catenin expression in hepatocellular carcinoma:A possible participation ofβ-catenin in the dedifferentiation process. J Gastroenterol Hepatol 17:994-1000, 2002.
 
11) Nakashima Y, et al:P 53 overexpression in small hepatocellular carcinomas containing two different histologic grades. Int J Oncol 12:455-459, 1998.
 
12) 日本肝癌研究会:臨床・病理:原発性肝癌取扱い規約. 第4版,金原出版, 東京, 2001.
 
13) 中島 収:小型肝細胞癌の病理-特に肉眼型と門脈侵襲肝内転移. 肝細胞癌治療マニュアル (山中若樹他編), p 9-13. 南江堂, 東京, 2002.
 
14) 杉原茂孝, 他:肉腫様変化を示す肝細胞癌の臨床病理学的研究. 肝臓 29:71-76, 1988.
 
15) Yamaguchi R, et al:Hepatocellular carcinoma with ssarcomatous change:a clinicopathological and immunohistochemical study of 6 surgical cases. Oncology reports 4:525-529, 1997.
 
16) Yamaguchi R, et al:Hepatoellular carcinoma with an unusual neuroendocrine component. Pathol Int 54:861-865, 2004.
 
17) 中島 収他:大型高分化型肝細胞癌か肝細胞腺腫か?-欧米肝病理専門医による病理診断との比較検討-. 肝臓 Supple (1), 43, 2002.
 
18) Kurogi M, et al:Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 21:1470-1477, 2006.
PubMed
19) Wada Y, et al:Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:407-414, 1998.
 
20) 中島 収:Fibrolamellar carcinoma 肝癌の診断と治療-最近の研究動向-. 日臨59増刊号 6, 大阪 2001.
 
P.41 掲載の参考文献
1) Hanahan D, et al:The Hallmarks of Cancer. Cell 100:57-70, 2000.
PubMed
2) Sasaki Y, et al:Does oxidative stress paricipate in the development of hepatocellular carcinoma? J Gastroenterol 41:1135-1148, 2006.
 
3) Hussain S P, et al:Molecular epidemiology of human cancer:contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58:4023-4037, 1998.
PubMed
4) Shay JW, et al:New evidence for the insertion of mitochondrial DNA into the human genome:significance for cancer and aging. Mutat Res 275:227-235, 1992.
PubMed
5) Kanai Y, et al:The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 71:355-359, 1997.
 
6) Yang B, et al:Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma. Am J pathol 163:1101-1107, 2003.
PubMed
7) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
8) Abou-Elella A, et al:C-myc amplificationin hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 9:95-98, 1996.
 
9) Nishida N, et al:Amplification and overexpression of the cyclin DI gene in aggressive human hepatocellular carcinoma. Cancer Res 54:3107-3110, 1994.
 
10) de La Coste A, et al:Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95:8847-8851, 1998.
PubMed
11) Spandau D F, et al:Transactivation of viral enhancers by the hepatitis B virus X protein. J Virol 62:427-434, 1988.
 
12) De Souza A T, et al:Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10:1725-1729, 1995.
PubMed
13) Murakami Y, et al:Aberrations of the tumor suppressor p 53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51:5520-5525, 1991.
 
14) Oda T, et al:p 53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52:6358-6364, 1992.
 
15) Shin E C, et al:Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 134:155-162, 1998.
PubMed
16) Chang J, et al:Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci 76:1883-1893, 2005.
PubMed
17) Martin J, et al:Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular cacrcinoma. Gastroenterology 130:1465-1475, 2006.
 
18) Gottlob K, et al:The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 273:33347-33353, 1998,
PubMed
19) Ito Y, et al:Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma Hepatology 27:951-958, 1998.
PubMed
20) Strand S, et al:Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-A mechanism of immune evasion? Nat Med 2:1361-1366, 1996.
 
21) Ferber MJ, et al:Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers, Oncogene 22:3813-3820, 2003.
PubMed
22) El-Assal ON, et al:Clinical significance of microvessel density and vascular endothellal growth factor expression in hepatocellular carcinoma and surrounding liver possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554-1562, 1998.
 
P.46 掲載の参考文献
1) Fottovich G, et al:Hepatocellular carcinoma in cirrhosis:incidence and risk factors. Gastroenterology 127:S 35-50, 2004.
 
2) Luo JC, et al:Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. Cancer 86:799-804, 1999.
PubMed
3) Hirayama T, et al:Hypercholesterolemia in rats with hepatomas:increased oxysterols accelerate efnux but do not inhibit biosynthesis of cholesterol. Hepatology 44:602-611, 2006.
 
4) Ishida S, et al:Big insulin-like growth factor II-producing hepatocellular carcinoma associated with hypoglycemia Intern Med 34:1201-1206, 1995.
PubMed
5) 猪俣絵里子, 他:高コレステロール血症.血小板増多症, 低血糖を合併した肝細胞癌の1例. 日消誌 104:1231-1235, 2007.
Medical*Online
6) Sakisaka S, et al:Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia:immunohistochemical evidence. Hepatology 18:1357-1362, 1993.
PubMed
7) Hwang S J, et al:Thrombocytosis:aparaneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 10:2472-2477, 2004.
 
8) Luo J C, et al:Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 49:1315-1319, 2002.
PubMed
9) Sugitani S, et al:Hyperplastic foci reflect the risk of multicentric development of human hepatocellular carcinoma. J Hepatol 28:1045-1053, 1998.
PubMed
10) Oikawa T, et al:Multistep and muticentric development of hepatocellular carcinoma:histological analysis of 980 resected nodules. J Hepatol 42:225-229, 2005.
 
11) Sakamoto M, et al:Multicentric independent development of hepatocellular carcinoma revealed by analysisi of hepatitis b virus integration pattern. Am J Surg Pathol 13:1064-1067, 1989.
 
12) Tsuda H, et al:Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res 52:1504-1509, 1992.
PubMed
13) Oda T, et al:Mutation pattern of the p 53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674-3678, 1992.
 
14) Yamamoto T, et al:Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 29:1446-1452, 1999.
PubMed
15) Nakashima O, et al:Pathomorphologic characteristics of small hepatocellular carcinoma:A special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 22:101-105, 1995.
PubMed
16) Matsui O, et al:Dynamic sequential computed tomography during arterial portography in the detection of hepatic neoplasms. Radiology 146:721-727, 1983.
PubMed
17) Kudo M, et al:Sonography with intraarterial infusion of carbon dioxide microbubbles (sonographic angiography):value in differential diagnosis of hepatic tumors. Am J Roentgenol 158:65-74, 1992.
 
18) Ueda K, et al:Vascular supply in adenommatous hyperplasia of the liver and hepatocellular carcinoma:amorphometric study. Hum Pathol 23:619-626, 1992.
 
19) Hayashi M, et al:Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis:evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roenterol 712:969-976, 1999.
 

第3章 診断

P.55 掲載の参考文献
1) 日本肝癌研究会, 肝癌追跡調査委員会:第17回全国原発性肝癌追跡調査報告. 進行印刷出版, 京都, 2006.
 
2) Ono E, et al:Platelet count re到ects stage of chronic hepatitis C. Hepatology Research 15:192-200, 1999.
 
3) Shiratori Y, et al:Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517-524, 2000.
PubMed
4) Yoshida H, et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131:174-181, 2000.
 
5) 小林功幸:肝臓癌診断へのアプローチ. 臨検 49 (11):1201-1205, 2005.
 
6) 鳥巣雄一:肝機能検査の総合評価. 別冊・医のあゆみ, 消化器疾患state of arts, 肝・胆・膵 (竹井謙之, 他), p 252-256. 医歯薬出版, 東京, 2006.
 
7) 太田英樹:腫瘍マーカーの種類とその生物学特性, アイソザイム. 日臨54 (6):1505-1509, 1996.
 
8) 青柳 豊:肝細胞癌の腫瘍マーカー. 別冊・医のあゆみ, 消化器疾患 state of arts, 肝・胆・膵 (竹井謙之, 他), p 273-277. 医歯薬出版, 東京, 2006.
 
9) Aoyagi Y, et al:The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61:769-774, 1988.
PubMed
10) Aoyagi Y, et al:Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 2:1353-1354, 1985
PubMed
11) Liebman H A, et al:Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427-1431, 1984.
PubMed
12) Koike Y, et al:Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma:a prospective analysis of 227 patients. Cancer 91 (3):561-569, 2001.
PubMed
13) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班:腫瘍マーカー. 科学的根拠に基づく肝癌診療ガイドライン2005年版, p 42-49. 金原出版,東京, 2005.
 
P.63 掲載の参考文献
1) Abelev G I:Production of embryonal serum alpha-globulin by hepatomas:review of experimental and clinical data. Cancer Res 28:1344-1355, 1968.
PubMed
2) 日本肝癌研究会, 肝癌追跡調査委員会:第17回全国原発性肝癌追跡調査報告. 株式会社メディア・プランニング, 2006.
 
3) Liebman H A, et al:Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Eng J Med 310:1427-1431, 1984.
 
4) Okuda H, et al:Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85:812-818, 1999.
PubMed
5) Mita Y, et al:Usefulness of sensitive determination of des-gamma-carboxy prothrombin in the early diagnosis of patients with hepatocelular carcinoma. Cancer 82:1643-1648, 1998.
 
6) 鈴木 宏, 他:PIVKA-II測定キット ED-036の臨床評価. 肝胆膵 33:1069-1076, 1996.
 
7) Aoyagi Y, et al:Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma Gann 75:809-815, 1984.
 
8) Aoyagi Y, et al:Fucosylation of serum alpha-fetoprotein in patient with primary hepatocellular carcinoma. Biochim Biophys Acta 830:217-223, 1985.
PubMed
9) Aoyagi Y, et al:Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma:Presence of fucosylated and non-fucosylated triantennary glycans. Brit J Cancer 67:486-492 1993.
PubMed
10) Aoyagi Y, et al:Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet ii:1353-1354, 1985.
 
11) Aoyagi Y, et al:The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61:769-774, 1988.
PubMed
12) Taketa K, et al:Antiboby-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin athnity electrophoresis in agarose gels. Electrophoresis 6:492-497, 1985.
 
13) Yamashita F, et al:Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111:996-1001, 1996.
PubMed
14) Aoyagi Y, et al:Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 83:2076-2082, 1998,
PubMed
15) Hayashi K, et al:Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94:3028-3033, 1999.
PubMed
16) Aoyagi Y, et al:The fucosylation index of serum α-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatolgy Res 23 (4):287-295, 2002.
 
17) Kobayashi M, et al:The fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to the low concentration of serum alpha-fetoprotein. Hepatolgy Res 2007. (in pres)
 
18) 青柳 豊, 他:AFP-L3分画および血流中癌細胞テロメラーゼを指標とした肝細胞癌のサーベイランスの有用性に関する研究. 厚生労働科学研究費補助金 (肝炎等克服緊急対策研究事業) 総括研究報告書. (平成18年度).
 
19) Zhu ZW, et al:Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48:558-564, 2001.
PubMed
20) Capurro M, et al:Glypican-3:a novel serum and histochemical marker for hepato Cellular Carcinoma Gastroenterology 125:89-97, 2003.
 
21) Hippo Y, et al:Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64 (7):2418-2423, 2004.
PubMed
P.71 掲載の参考文献
1) Yoshida T, et al:Ultrasonographic differentiation of hepatocellular carcinoma from metastatic liver cancer. J Clin Ultrasound 15 (7):431-437, 1987.
PubMed
2) Maringhini A, et al:Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 33 (1):47-51, 1988
PubMed
3) Itai Y, et al:小肝腫瘍の超音波像. Radiation Medicine 5 (1):141-149, 1987,
 
4) 工藤正俊, 他:どのようなときに造影エコーを行うか. 肝癌診療マニュアル (日本肝臓学会), p 41-44. 医学書院, 東京, 2007.
 
5) 鈴木陽一, 他:映像技術. 超音波造影ガイドブック (森安史典, 他編), p 21-27. 金原出版, 東京, 2003.
 
6) 飯島尋子, 他:次世代造影剤による造影超音波診断. 肝・胆・膵47:203-212, 2003.
 
P.80 掲載の参考文献
1) Hu H, et al:Four multidetector-row helical CT:Image quality and volume coverage speed. Radiology 215:55-62, 2000.
PubMed
2) Sakamoto M, et al:Multicentric development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg 13:1064-1067, 1989.
 
3) Sakamoto M, et al:Early stages of multistep hepatocarcinogenesis:adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 22:172-178, 1991.
PubMed
4) Matsui O, et al:Benign and malignant nodules in cirrhotic livers:distinction based on blood supply. Radiology 178:493-497, 1991.
PubMed
5) Hayashi M, et al:Correlation between the blood supply and grade of malignancy of hepatocellular nodues associated with liver cirrhosis:evaluation by CT during intraarterial injection of contrast medium. AJR 172:969-976, 1999.
PubMed
6) Ueda K, et al:Vascular supply in adenomatous hyperplasia of the liver and hepatocelular carcinoma:amorphometric study. Hum Pathol 23:619-626, 1992.
 
7) 松井 修:肝細胞癌の血行動態:動注CTによる解析とその意義. 肝臓42:503-511, 2001.
 
8) Foley W D, et al:Multiphase Hepatic CT with a Multirow Detector CT Scanner. AJR175:679-685, 2000.
PubMed
9) Murakami T, et al:Hypervascular Hepatocellular Carcinoma:Detection with Double Arterial Phase Multidetector Row Helical CT. Radiology 218:763-767, 2001.
 
10) Ueda K, et al:Hypervascular hepatocellular carcinoma:evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 206 (1):161-166, 1998.
PubMed
11) Kadoya M, et al:hepatocellular carcinoma:correlation of MR imaging and histologic findings. Radiology 183:819-825, 1992.
PubMed
12) 角谷真澄:肝癌のMRI:現況と展望. 肝臓 42:518-527, 2002.
 
13) Clement O, et al:Liver imaging with Ferumoxides (Feridex):Fundamentals, controversies, and practical aspects. Top Mag Reson Imaging 9:167-182, 1998.
 
14) Matsui O, et al:Adenomatous hyperplastic nodules in the cirrhotic liver:differentiation from hepatocellular carcinoma with MR imaging. Radiology 173:123-126, 1989.
PubMed
15) 小原 真:新しい高速撮像法:parallel imaging. Parallel imagingの概要. 臨画像19:848-857, 2003.
 
16) Vogl T J, et al:Liver tumors:Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59-67, 1996.
PubMed
P.88 掲載の参考文献
1) International Union Against Cancer (UICC):In:TNM classification of malignant tumors, 6th ed (Sobin L H, et al, eds), pp 81-83. New York, Wiley-Liss, 2002.
 
2) 日本肝癌研究会:臨床・病理原発性肝癌取扱い規約 (第4版), 金原出版東京, 2000.
 
3) Child C G:The liver and portal hypertension, p 50. MPCS W B, Saunders, Philadelphia, 1964.
 
4) Pugh RN et al:Transection of the oesophageus for bleeding oesophageal varices Br J Surg 60 (8):646-649, 1973.
 
5) The Cancer of the Liver Italian Program (CllP) Investigators:A new prognostic system for hepatocellular carcinoma:A retrospective study of 435 patients. Hepatology 28:751-755, 199&
 
6) Lovet J M, et al:Prognosis of hepatocellular carcinoma:The BCLC staging classification. Semin Liver Dis 19:329-337, 1999.
 
7) Kudo M, et al:Prognostic staging system for hepatocellular carcinoma (CLIP score):its value and limitations, and a proposal for A new staging system, the Japan integrated staging score (JIS). J Gastroenterol 38:207-215, 2003,
 
P.100 掲載の参考文献
1) Itai Y, et al:Computed tomography of cavernous hemangioma of the Liver. Radiology 137:149-155, 1980.
PubMed
2) Grandin C B, et al:Ferumoxides and Tc-99m sulfur colloid:comparison of the tumor-to-liver uptake in focal nodular hyperplasia. JMRI 7:125-129, 1997.
PubMed
3) Grazioli L, et al:Liver adenomotosis:clinical pathologic, and imaging findings in 15 patients. Radiology 216:395-402, 2000.
 
4) 中島 収.他:アルコール多飲者の肝過形成結節に関する臨床病理学的研究. 肝臓37:704-713, 1996.
 
5) Kutami R, et al:Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282-289, 2000.
 
6) 岸本幸広, 他:肉腫様肝細胞癌の2例-特に画像診断について. 肝臓34:837-843, 1993.
 
7) Shimizu A, et al:Cirrhosis or chronic hepatitis:evaluation of small (<or:=2-cm) early enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 226:550-555, 2003.
 
8) Matsui O, et al:Pseudolesion in segment IV of the liver at CT during arterial portography:correlation with aberrant gastric venous drainage, Radiology 193:31-35, 1994.
PubMed
9) Yoshikawa J, et al:Focal fatty change of the liver adjacent to the falciform ligament; CT and sonographic findings in five surgically confirmed cases. AJR 149:491-494, 1987.
 
10) Wachaberg R H, et al:Blood flow characteristics of vessels in the ligamentum teres at color Doppler sonography:findings in healthy bolunteers and in patients with portal hypertension. AJR 164:1403-1405, 1995.
 

第4章 管理・治療

P.107 掲載の参考文献
1) Kiyosawa K, et al:Hepatocellular carcinoma:recent trend in Japan. Gastroenterology 127 (Suppl 1) S 17-26, 2004.
 
2) Yen T S:Hepadonaviral X protein:review of X protein. J Biomed Sci 3:20-30, 1996.
 
3) Kao J H, et al:Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334, 2003.
PubMed
4) Chen C J, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA. JAMA 295:65-73, 2006.
PubMed
5) Yuen M F, et al:Prognostic determinants for chronic hepatitis B in Asians:therapeutic implications. Gut 54:1610-1614, 2005.
PubMed
6) Kim CM, et al:HBx gene of hepatitis B virus induces liver cancer in transgenic mouse. Nature 351:317-320, 1991.
PubMed
7) Minami M, et al:Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24:4340-4348, 2005.
PubMed
8)International Interferon-alpfa Hepatocellular Carcinoma Study Group:Effect of interferon-alpfa on progression of cirrhosis to hepatocellular carcinoma:a retrospective cohort study. Lancet 351:1535-1539, 1998.
 
9) Ikeda K, et al:Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy:Long-term follow-up of a pilot study. J Gastroenterol Hepatol 20:95-102, 2005.
PubMed
10) Liaw Y F, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
11) Matsumoto A, et al:Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184, 2005.
PubMed
12) Moriya K, et al:Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcino genesis. Cancer Res 61:4365-4370, 2001.
 
13) Okuda M, et al:Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366-375, 2002.
PubMed
14) Okanoue T, et al:Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage:A retrospective study in 1148 patients. J Hepatol 30:653-659, 1999.
 
15) Okanoue T, et al:Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 23:62-77, 2002.
 
16) Okanoue T, et al:Guideline for antiviral therapy of HCV carriers with normal serum aminotransferase based on plate counts-focused on the inhibition of the development of hepatocellular carcinoma. Hepatol Res (in press)
 
17) Kato J, et al:Normalization of elevated hepatic 8-hydroxy-2-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702, 2001.
PubMed
P.113 掲載の参考文献
1) Tsukuma H, et al:Risk factors for hepatocellular carcinoma among Patients with chronic liver disease. N Engl J Med 328 (25):1797-1801, 1993.
PubMed
2) Donato F, et al:Alcohol and hepatocellular carcinoma the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (4):323-331, 2002.
PubMed
3) Yuen M F, et al:Early detection of hepatocellular carcinoma increases the chance of treatment:Hong Kong experience. Hepatology 31 (2):330-335, 2000.
PubMed
4) Bolondi L, et al:Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma:a cost effective analysis. Gut 48 (2):251-259, 2001.
 
5) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究斑編:診断およびサーベイランス. 肝癌診療ガイドライン2005年版. p 27-66. 金原出版,東京, 2005.
 
6) Aoyagi Y, et al:Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet ii:1353-1354, 1985.
 
7) Liebman H A, et al:Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427-1431, 1984.
PubMed
8) 日本肝癌研究会, 肝癌追跡調査委員会編:第 17回全国原発性肝癌追跡調査報告 (2002-2003). 日本肝癌研究会事務局, 京都, 2006.
 
9) Caturelli E, et al:Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detectioll of hepatocellular carcinoma. Am J Gastroenterol 97 (2):397-405, 2002.
PubMed
10) Choi B I, et al:Vascularity of hepatocellular carcinoma:assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology 214 (2):381-386, 2000.
PubMed
11) Strobel D, et al:Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound 28 (1):1-13, 2000.
PubMed
12) Chalasani N, et al:Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 94:2988-2993, 1999.
PubMed
13) Rode A, et al:Small nodule detection in cirrhotic livers:evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25 (3):327-336, 2001.
 
14) Stoker J, et al:Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut 51 (1):105-107, 2002.
PubMed
15) Imai Y, et al:Super paramagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma correlation with histological grading. Hepatology 32 (2):205-212, 2002.
 
16) Matsui O, et al:Dynamic computed tomography during arterial portography:the most sensitive examination for small hepatocellular carcinomas. J Comput Assist Tomogr 91:19-24, 1985.
 
17) Kudo M, et al:Small heptocellular carcinoma:diagnosis with US angiography with intraarterial CO2 microbubbles. Radiology 182 (1):155-160, 1992.
 
18) Chen R C, et al:Detection of vasculature in small hepatocellular carcinoma, and dysplastic nodules evaluated with carbon dioxide ultrasonography and angiography. Acta Radiol 43 (1):66-70, 2002.
 
19) Hertz G, et al:Fine-needle aspiration biopsy of the liver:a multicenter study of 602 radiologically guided FNA. Diagn Cytopathol 23 (5):326-328, 2002.
 
20) Miyano S, et al:Occurrence of hepatocellular carcinoma 4. 5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 14:928-930, 1999.
PubMed
P.121 掲載の参考文献
1) 杉浦信之, 他:超音波映像下経皮的腫瘍内エタノール注入による小肝癌の治療. 肝臓 24:920, 1983.
 
2) 谷川久一:腫瘍内エタノール注入療法の進歩. 消外14:1389-1395, 1991.
 
3) Seki T, et al:Ultrasonically guided percutaneous microwave coagulation small hepatocellular carcinoma 817-825, 1994.
PubMed
4) Lu D S, et al:Radiofrequency hepatocellular carcinoma:ablation of treatment success as defined by hisyologic examination of the explanted liver. Radiology 234:954-960, 2005.
PubMed
5) Sala M, et al:Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma Hepatology 40:1352-1360, 2004.
PubMed
6) Yamazaki T, et al:Percutaneous radiofrequency ablation with cooled electrodes. combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. J Gastroenterol 40:171-178, 2005.
 
7) Izumi N, et al:Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 91:949-956, 2001.
PubMed
P.128 掲載の参考文献
1) Parkin D M, et al:Estimating the world cancer burden:Globocan 2000. Int J Cancer 94:153-156, 2001.
PubMed
2) Llovet J M, et al:Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:resection versus transplantation. Hepatology 30:1434-1440, 1999.
PubMed
3) Doyon DMA, et al:L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol 17:593-603, 1974.
 
4) Yamada R, et al:Transcatheter arterial embolization in unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 13:135-139, 1990.
PubMed
5) Uchida H, et al:Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13:140-145, 1990.
PubMed
6) Matsui O, et al:Small hepatocellular carcinoma:treatment with subsegmental transcatheter arterial embolization. Radiology 188:79-83, 1993.
PubMed
7) Llovet J M, et al:Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:arandomised controlled trial. Lancet 359:1734-1739, 2002.
 
8) Lo C M, et al:Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002.
PubMed
9) Camma C, et al:Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials. Radiology 224:47-54, 2002.
PubMed
10) Llovet J M, et al:Systematic review of randomized trials for unresectable hepatocellular carcinoma Chemoembolization improves survival. Hepatology 37:429-442, 2003.
PubMed
11) 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告 (2002-2003). 肝臓48 (3):117-140, 2007.
 
12) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班:肝癌診療ガイドライン. 金原出版, 東京, 2005.
 
13) Bruix J, et al:Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005.
PubMed
14) Chen C, et al:Bacterial infections associated with hepatic arteriography and transarterial embolization for hepatocellular carcinoma:A prospective study. Clin Infect Dis 29:161-166, 1999.
PubMed
15) Marelli L, et al:Transarterial therapy for hepatocellular carcinoma:which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25, 2007.
PubMed
16) Rand T, et al:Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 28:313-318, 2005.
PubMed
17) Varela M, et al:Chemoembolization of hepatocellular carcinoma with drug eluting beads:Efficacy and doxorubicin pharmacokinetics, J Hepatol 46:474-481, 2007.
PubMed
18) Miyayama S, et al:Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas:relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 18:365-376, 2007.
PubMed
19) Bruix J, et al:Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:results of a randomized, controlled trial in a single institution. Hepatology 27:1578-1583, 1998.
 
20) GETCH:A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261, 1995.
 
21) Takayasu K, et al:Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system:analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 176:681-688, 2001.
PubMed
22) Takayasu K, et al:Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-469, 2006.
PubMed
23) 日本肝癌研究会:肝癌治療直接効果判定基準. 肝臓 35:193-205, 1994.
 
24) 日本肝癌研究会:肝癌治療直接効果判定基準 (2004年改訂版). 肝臓45:380-385, 2004.
 
25) Yamakado K, et al:Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma Short-term recurrences and survival. Oncol Rep 11:105-109, 2004.
PubMed
26) Graziadei I W, et al:Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcoine. Liver Transp 19:557-563, 2003.
 
27) Lau W Y, et al:Adjuvant intra-arterial ione-131-labelled lipiodol for resectable hepatocellular carcinoma:A prospective randomised trial. Lancet 353:797-801, 1999.
 
P.138 掲載の参考文献
1) Llovet J M, et al:Systematic review of randonlized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival. Hepatology 37:429-442, 2003.
PubMed
2) Patt Y Z, et al:Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma:effect of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12:1204-1211, 1994.
 
3) Toyoda H, et al:The efficacy of continuous local arterial infusion of 5-fiuorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295-299, 1995.
 
4) Ando E, et al:Hepatic infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases. Cancer 95:588-595, 2002.
PubMed
5) Yamasaki T, et al:Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 40:70-78, 2005.
PubMed
6) Sakon M, et al:Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 15:435-442, 2002.
 
7) Kaneko S, et al:Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 62 (Suppl 1):69-73, 2002.
 
8) Obi S, et al:Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion, Cancer 9:1990-1997, 2006.
PubMed
9) Park J Y, et al:Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110 (1):129-137, 2007.
PubMed
10) Nagamatsu H, et al:Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 99 (12):2369-, 2375, 2004.
 
11) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班:化学的根拠に基づく肝癌診療ガイドライン2005年度版. p 96-99, 金原出版, 東京, 2005.
 
12) Fukuda S, et al:Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus:report of 19 cases. Surgery 131 (3):300-310, 2002.
 
13) Kurokawa Y, et al:Molecular prediction of response to 5-fuluorouracil and interferonalpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 10:6029-6038, 2004.
 
14) Fan J, et al:Efficacy of different strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 11 (8):1215-1219, 2005.
PubMed
15) Tang Z Y, et al:Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma:evaluation with analysis of 72 patients. World J Surg 19:784-789, 1995.
 
P.149 掲載の参考文献
1) Ishikawa T, et al:High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 16:1274-1281, 2001.
PubMed
2) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班編:科学的根拠に基づく肝癌診療ガイドライン2005年版, 金原出版, 東京, 2005.
 
3) Okada S, et al:A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50:22-26, 1993.
PubMed
4) Ikeda M, et al:Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 66:24-31, 2004.
PubMed
5) 石川 達, 他:動注用アイエーコールによる腫瘍壊死を病理学的に確認しえた肝細胞癌切除例. 肝臓48:27-31, 2007.
 
6) Osada S, et al:Mechanism of novel vitamin Kanalog induced growth inhibition in human hepatoma cell line. J Hepatol 34:676-682, 2001.
PubMed
7) Naquib F N M, et al:Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985.
 
8) Diasio R B, et al:Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinetic 16:215-237, 1989.
PubMed
9) Ishikawa T, et al:Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus related decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Am J Gastroenterology 94:1682-1685, 1999.
 
10) Ishikawa T, et al:Improved survival with oral administration of enteric-coated tegafur/uracil for advanced Stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 16:452-459, 2001.
 
11) 石川 達, 他:進行性肝細胞がんに対するウラシル系経口制がん剤の臨床的意義. 第21回犬山シンポジウム高度進行肝細胞癌, 生体部分肝移植, B型, C型慢性肝炎治療, 犬山シンポジウム記録刊行会編, pp 6-16. 中外医学社, 東京, 2000.
 
12) 石川 達,他:肝細胞癌に対する化学療法の現況. Cancer Up To Date 3:26-30, 2001.
 
13) Ikeda K, et al:A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18:204-210, 1995.
PubMed
14) 武元良祐, 他:テガフール ギメラシル オテラシルカリウム配合カプセル剤 (TS-1) が奏効した肝細胞癌の一例. 日消誌100:1123-1128, 2003.
 
15) Shiraka T, et al:Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557, 1996,
 
16) Sakon M, et al:Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442, 2002.
PubMed
17) Ando E, et al:Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases. Cancer 95:588-595, 2002.
PubMed
18) Kusumoki M, et al:The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinoma. Oncol Rep 5:547-552, 1999.
 
19) 石川 達, 他:切除不能膵癌肝転移に対してAngiotensin-II (AT-II) 併用昇圧動注化学療法, UFT-E全身化学療法が奏効した1例. 癌と化療28:521-525, 2001.
 
20) 石川 達, 他:Pharmacokinetic Modulating Chemotherapy (PMC) を応用した Angiotensin-II (AT-II) 併用昇圧動注化学療法により, Down Stagingが得られた腹膜播種進行胃癌の1例. 癌と化療28:1137-1140, 2001.
 
21) 石川 達, 他:Angiotensin-II(AT-II)併用 Pharmacokinetics Modulating Chemotherapy (PMC) 昇圧変法動注化学療法が奏功した多発肝転移リンパ節転移進行胃癌の1例. 癌と化療30:1151-1155, 2003.
 
22) 高安幸生:EEP療法による原発性肝細胞癌の動注化学療法. 日臨59:624-628, 2001.
 
23) 石川 達,他:CO2-DSAによりリザーバー留置し, 化学療法が奏効したヨード過敏の門脈腫瘍塞栓肝細胞癌の1例. 肝臓45:216-221, 2004.
 
24) Ishikawa T, et al:Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil-Pilot Study (in submission).
 
25) Ishikawa T, et al:Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 19:1423-1426, 2004.
 
26) 左近賢人, 他:肝癌の治療戦略Stage IV肝癌の治療と再発予防. 外科治療93:53-58, 2005.
 
27) 長谷川 潔, 他:肝細胞癌に対する治癒切除後のUFT補助療法の有用性に関するRCT. 第42回日本肝癌研究会抄録集, p 69, 2006.
 
28) 上田弘樹, 他:肝細胞癌に対する肝動脈塞栓術後Tegafur/Uracil (UFT) 補助療法の有用性と安全性. 第43回日本癌治療学会総会抄録集40:83, 2005.
 
29) Schuierer M M, et al:Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 16:451-456, 2006.
PubMed
P.157 掲載の参考文献
1) 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告 (2002～2003). 日本肝癌研究会事務局, 2006.
 
2) 幕内雅敏他:肝硬変合併肝癌治療のStrategy. 外科診療29:1530-1536, 1987.
 
3) 科学的根拠に基づく肝癌診療ガイドライン作製に関する研究班編:科学的根拠に基づく肝癌診療ガイドライン2005年版. 金原出版, 東京, 2005.
 
4) 日本肝癌研究会:臨床・病理原発性肝癌取扱い規約, 第4版. 金原出版, 東京, 2006.
 
5) Mazzaferro V, et al:Prophylaxis against HCV recurrence after liver transplantation:effect of interferon and ribavirin combination. Transplantation Proc 29:519-521, 1997.
PubMed
6) Pugh RNH, et al:Transection of the oesophagus for bleeding oesophageal varices. Br J surg 60:646-649, 1973.
 
7) Lau H, et al:Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J surg 84:1255-1259, 1997.
PubMed
8) Imamura H, et al:Prognostic significance of anatomical resection and des-gamma carboxy prothrombin in patients with hepatocellular car Cinoma. Br J surg 86:1032-1038, 1999.
 
9) Yamanaka N, et al:Prognostic factors, after hepatectomy for hepatocellular carcinoma. Cancer 65:1104-1110, 1990.
PubMed
10) Yamamoto M, et al:Effectiveness of systematized hepatectomy with Glisson:spedicle transaction at the hepatic hilus for small nodular hepatocellular carcinoma:retrospective analysis, Surgery 130:443-448, 2001.
 
11) Kosuge T, et al:Long-term results after resection of hepatocellular carcinoma:experience of 480 cases. Hepatogastroenteroloogy 40:328-332, 1993.
PubMed
12) Minagawa M, et al:Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann surg 238:703-710, 2003.
PubMed
13) Makuuchi M, et al:Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 161:346-350, 1985.
PubMed
14) Takasaki K, et al:Highly anatomically systematized hepatic resection with Glissonean sheath code transaction at the hepatic hilus. Int surg 75:73-77, 1990.
 
15) Makuuchi M, et al:Preoperative portal vein embolization to increase safety of major hepatectomy for hilar bile duct carcinoma:apreliminary report. Surgery 107:521-527, 1990.
 
16) Kinoshita H et al:Preoperative portal vein embolization for hepatocellular carcinoma. Worg J Surg 10:803-808, 1986.
 
17) Belghiti J, et al:Liver hanging maneuver:a safe approach to right hepatectomy with:out liver mobilization. J Am Coll Surg 193:109-111, 2001.
 
18) 中村典明, 他:高度閉塞性黄疸で発症した胆管内発育型肝細胞癌の1切除例. Liver cancer 12:172-181, 2006.
Medical*Online
19) Arii S, et al:Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinoma:a retrospective nationwide survey in Japan. Hepatology 32:1224-1229, 2000.
PubMed
20) Chen M F, et al:Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers:univariate and multivariate analysis. World J surg 27:443-447, 2003.
PubMed
P.164 掲載の参考文献
1) O' Grady J D, et al:Liver transplantation for malignant disease. Ann Surg 207:373-379, 198&
 
2) Ringe B, et al:Surgical treatment of hepatocellular carcinoma:Experience with liver resection and transplantation in 198 patients. World J Surg 15:270-283, 1991.
PubMed
3) Iwatsuki S, et al:Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214:221-229, 1991.
PubMed
4) Mazzaferro V, et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699, 1996.
PubMed
5) United Network for Organ Sharing. Policy 3.6. Available at:www. unos. org.
 
6) Todo S, et al:Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg 240:451-461, 2004.
PubMed
7) Takada Y, et al:Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 12:912-919, 2006.
PubMed
8) Yao F Y, et al:Liver transplantation for hepatocellular carcinoma:Expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403, 2001.
PubMed
9) 日本肝臓学会ホームページ http://www. jsh. or. jp/medical/liver/
 
10) Ito T, et al:Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl (in press)
 
P.175 掲載の参考文献
1) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班:科学的根拠に基づく肝癌診療ガイドライン2005年度版.金原出版, 東京, 2005.
 
2) 日本肝癌研究会:第17回原発性肝癌追跡調査報告 (2002-2003), 2006.
 
3) Emami B, et al:Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122, 1991.
PubMed
4) 大原 潔, 他:肝癌集学的治療における肝部分照射の放射線耐容. 日本医放会誌50:146-154, 1990.
 
5) Kim T H, et al:Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 29:568-575, 2006.
PubMed
6) Mornex E et al:Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase II RTF-1 trial Int J Radiat Oncol Biol Phys 66:1152-1158, 2006.
 
7) Seong J, et al:Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 27:30-35, 2003.
PubMed
8) Takeda A, et al:Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies:Preliminary results for efficacy and toxicity. Hepatol Res 2007. (in press)
PubMed
9) Choi B O, et al:Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. JPn J Clin Oncol 36:154-158, 2006.
PubMed
10) Cheng S H, et al:A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 14:1025-1033, 1999.
PubMed
11) Sisterson J:A newsletter for those interested in proton, light ion and heavy charged particle radiotherapy. PARTICLES 36:11, 2005.
 
12) Matsuzaki Y, et al:A new, effective, and safe therapeutic option using Proton irradiation for hepatocellular carcinoma. Gastroenterology 106:1032-1041, 1994.
PubMed
13) Chiba T, et al:Proton beam therapy for he patocellular carcinoma:a retrospective review of 162 patients. Clin Cancer Res 11:3799-3805, 2005.
 
14) Kawashima M, et al:Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma, J Clin Oncol 23:1839-1846, 2005.
PubMed
15) 松崎靖司, 他:肝細胞癌に対する陽子線照射療法の効用-とくにQOLの面より. 肝臓病Up-date (三田村圭二編), p 150-156. 南光堂, 東京, 1997.
 
16) Kato H, et al:Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59:1468-1476, 2004,
PubMed
17) Butterfield L H:Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127:S 232-241, 2004.
 
18) Lai C L, et al:Recombinant interferon-alpha in inoperable hepatocellular carcinoma:A randomized controlled trial. Hepatology 17:389-394, 1993.
PubMed
19) Palmieri G, et al:Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 25:224-226, 2002.
PubMed
20) Takayama T, et al:Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:arandomised trial. Lancet 356:802-807, 2000.
PubMed
21) Margalit M, et al:Suppression of hepatocellular carcinoma by transplantation of exvivo immune-modulated NKT lymphocytes. Int J Cancer 115:443-449, 2005.
 
22) Lee W C, et al:Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells:aclinical trial. J Immunother (1997) 28:496-504, 2005.
 
23) Butterfield L H, et al:T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9:5902-5908, 2003.
PubMed
24) Kuang M, et al:Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10:1574-1579, 2004.
PubMed
25) Ohno T, et al:Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatol Res 37:276-285, 2007.
PubMed
P.184 掲載の参考文献
1) 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告 (2002～2003年).
 
2) 科学的根拠に基づく肝癌診療ガイドラインに関する研究班:科学的根拠に基づく肝癌診療ガイドライン-2005年版. 金原出版, 東京, 2005.
 
3) 社団法人 日本肝臓学会:肝癌診療マニュアル. 医学書院.東京, 2007.
 
P.191 掲載の参考文献
1) 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告 (2002-2003), 2006年
 
2) Takayasu K, et al:Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterol 131:461-469, 2006.
 
3) Todo S, et al:Living donor liver transplantation for adult patients with hepatocellular carcinoma;experiencee in Japan. Ann Surg 240:451-459, 2004.
PubMed
4) Kudo M, et al:Prognostic staging system for hepatocellular carcinoma (CLIP score):its value and limitations, and a proposal for new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterology 38:207-215, 2003.
 
5) Ikai I, et al:A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 41:884-892, 2006.
PubMed
6) The Cancer of the Liver Italian Program (CLIP) Investigators:Prospective validation of the CLIP score:A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840-845, 2000.
 
7) Farinati F, et al:How should patients with hepatocellular carcinoma be staged??Validation of a new prognostic system. Cancer 89:2266-2273, 2000.
PubMed
8) Levy I, et al:Staging of hepatocellular carcinoma:assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50:881-885, 2002.
 
9) Ueno S, et al:Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34:529-534, 2001.
PubMed
P.200 掲載の参考文献
1) Someya T, et al:Interferon lowers recurrence rate after surgical resection or ablation of hepatocellular carcinoma. A pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 41:1206-1213, 2006.
PubMed
2) Oon C J, et al:Lymphoblastoid alpha-interferon in the prevention of hepatocellular carcinoma (HCC) in high-risk HBsAg-positive resected cirrhotic HCC cases:a 14-year follow-up. Cancer Invest 21:394-399, 2003.
 
3) Sun H C, et al:Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma:A randomized clinical trial. J Cancer Res Clin Oncol 132:458-465, 2006.:
PubMed
4) Lo C M, et al:A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831-842, 2007.
PubMed
5) Jang J W, et al:A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43:233-240, 2006.
PubMed
6) Ikeda K, et al:Interferon-beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor -
 
7) Kubo S, et al:Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma A randomized controlled trial. Ann Int Med 134:963-967, 2001.
 
8) Shiratori Y, et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Int Med 138:299-306, 2003.
PubMed
9) Hung C H, et al:Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 20:1553-1559, 2005.
PubMed
10) Sakaguchi Y, et al:Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepaocellular carcinoma Intervirology 48:64-70, 2005.
 
11) Mazzaferro V, et al:Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:1543-1554, 2006.
PubMed
12) Dunk A A, et al:Human lymphoblastoid interferon:in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 2:419-429, 1986.
PubMed
13) Lai C L, et al:Recombinant interferon-alpha in inoperable hepatocellular carclnoma:A randomized controned trial. Hepatology 17:389-394, 1993.
 
14) Nakaji M, et al:IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 25:389-397, 2004.
PubMed
P.211 掲載の参考文献
1) Partel D, et al:Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3:75-84, 2005.
 
2) 石田 博, 他:肝細胞がんにおける合併症と治療を考慮した医療費推定の試み. 医療情報学24 (6):667-674, 2005.
 

第5章 ガイドライン

P.217 掲載の参考文献
1) 國土典宏, 他:肝癌治療の現状と今後の展開. 臨外59:261-265, 2004.
 
2) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班編:科学的根拠に基づく肝癌診療ガイドライン2005年版. 金原出版, 東京, 2005.
 
3) Arii S, et al:Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nation-wide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224-1229, 2000.
 
P.218 掲載の参考文献
4) Llovet J M, et al:Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:A randomized controlled trial. Lancet 359 (9319):1734-1739, 2002.
 
5) Mazzaferro V, et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699, 1996.
PubMed
6) Minagawa M, et al:Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. AIln Surg 233:379-384, 2001.
 
7) 國土典宏, 他:科学的根拠に基づく肝癌診療ガイドライン. 臨床に役立つ消化器疾患の診断基準病型分類・重症度の用い方 (棟方昭博, 他編), p 253-259. 日本メディカルセンター, 東京, 2006.
 
8) Eddy D M, et al:Clinical decision making:from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263 (22):3077, 3081, 3084, 1990.
 
9) Kokudo N, et al:Dissemination of evidencebased clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons, and primary care physicians. Gut 56:1020-1021, 2007.
 
10) Lencioni R A, et al:Small hepatocellular carcinoma in cirrhosis:randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235-240, 2003.
PubMed
11) Shiina S, et al:A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma Gastroenterology l 29:122-130, 2005.
 
12) Huang G T, et al:Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma:A prospective study. Ann Surg 242:36-42, 2005.
PubMed
13) Chen M S, et al:A prospective randomized trial comparing Percutaneous local ablative therapy and partial hepatectomy for hepatocellular carcinorna Ann Surg 243:321-328, 2006.
 
14) Hasegawa K, et al:Surgery or ablation for hepatocellular carcinoma. Ann Surg (in press)
 

書評

最近チェックした商品履歴

Loading...